Clinical Trial Update: A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

This report covers the completion of a Phase 1 study evaluating the CAR-T therapy C-CAR039 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• C-CAR039

Snippet

Sponsor: Peking University | Conditions: B Cell Non-Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED